Division of Hematology and Oncology

April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

By Leigh MacMillan
April 21, 2022

Biltibo receives career development award to support hematology research

Vanderbilt’s Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.

By Tom Wilemon
March 31, 2022

Black patients with cancer face worse COVID outcomes: study

Vanderbilt researchers have found that Black patients with cancer experienced significantly worse outcomes after COVID-19 diagnosis than non-Hispanic white cancer patients.

By Tom Wilemon
March 24, 2022

Berlin named interim leader of Hematology and Oncology

Jordan Berlin, MD, has been appointed interim leader of Vanderbilt’s Division of Hematology and Oncology in the Department of Medicine.

By Tom Wilemon
P. Brent Ferrell, MD, is part of a multidisciplinary team studying new approaches to understand and treat cancer.
March 17, 2022

Ferrell lands Mark Foundation for Cancer Research award

Vanderbilt’s Brent Ferrell, MD, is one of the recipients a 2022 Endeavor Award from the The Mark Foundation for Cancer Research.

By Tom Wilemon
March 7, 2022

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease

By Tom Wilemon
February 17, 2022

Park named director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.
By John Howser
February 17, 2022

Grant to support Haake’s research on kidney cancer

Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt's Scott Haake, MD.
By Tom Wilemon
January 25, 2022

Comprehensive framework outlined for addressing early-onset colorectal cancer research

New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.
By Tom Wilemon
December 24, 2021

Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate

New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.
By Tom Wilemon
December 21, 2021

New Clinician Spotlight: Katherine Walsh

Katherine Walsh, MD, has joined Vanderbilt University Medical Center as associate professor of Medicine in the Division of Hematology and Oncology.
By VUMC News and Communications
December 9, 2021

Cell signaling targets in leukemia

Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments.
By Leigh MacMillan
December 2, 2021

Reid selected for clinical trial development program

Vanderbilt's Sonya Reid, MD, MPH, has been selected to participate in the first cohort of the Bristol Myers Squibb Foundation Clinical Trial Diversity Career Development Program.
By Tom Wilemon
1 … 3 4 5 6 7 … 15